GH Research PLC Overview
Pro stress-test →GH Research is a clinical-stage biopharmaceutical company focusing on developing novel mebufotenin therapies for treating treatment-resistant depression (TRD). The company's lead asset GH001 is an inhalable mebufotenin candidate in Phase 2b clinical trials for TRD and Phase 2a trials for bipolar II disorder and postpartum depression.
Strategic Profile
Pro stress-test →GH Research develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies targeting psychiatric disorders. The company is advancing a multi-indication pipeline with inhalable and intravenous formulations, positioning itself in the emerging psychedelic-derived therapeutics market for treatment-resistant conditions.
Competitive Landscape
Pro stress-test →GH Research competes in the psychedelic-derived therapeutics space alongside other companies developing MDMA and psilocybin therapies for psychiatric indications. Direct competitors in TRD treatment include traditional antidepressant providers and emerging biotech firms developing esketamine analogs and novel mechanisms. GH Research's proprietary 5-MeO-DMT platform and inhalable/IV delivery approaches differentiate it in this nascent segment.
Industry Context
GH Research PLC operates in Psychedelic-derived therapeutics for psychiatric disorders.
Key facts
Founded: 2018 · Headquarters: Dublin, Ireland · Employees: 73 · Market cap: $1.48B